Enveric Biosciences Inc. (ENVB): Price and Financial Metrics


Enveric Biosciences Inc. (ENVB): $2.88

-0.12 (-4.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ENVB to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ENVB Stock Price Chart Interactive Chart >

Price chart for ENVB

ENVB Price/Volume Stats

Current price $2.88 52-week high $34.33
Prev. close $3.00 52-week low $1.57
Day low $2.87 Volume 43,100
Day high $3.20 Avg. volume 50,643
50-day MA $2.60 Dividend yield N/A
200-day MA $6.29 Market Cap 5.98M

Enveric Biosciences Inc. (ENVB) Company Bio


Enveric Biosciences Inc., formerly AMERI Holdings, Inc., is a patient-central biotechnology company. The Company is focused on enhancing lives of people affected by the side effects of cancer treatments, such as radiodermatitis and chemotherapy-induced peripheral neuropathy. The Company is engaged in leveraging its clinical developments derived from ... More


ENVB Latest News Stream


Event/Time News Detail
Loading, please wait...

ENVB Latest Social Stream


Loading social stream, please wait...

View Full ENVB Social Stream

Latest ENVB News From Around the Web

Below are the latest news stories about ENVERIC BIOSCIENCES INC that investors may wish to consider to help them evaluate ENVB as an investment opportunity.

Enveric Biosciences to Present at the 6th Annual Neuroscience Innovation Forum and Biotech Showcase during "J.P. Morgan Health Care Week 2023"

CAMBRIDGE, Mass., December 21, 2022--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression and addiction disorders, announced today that the company will present at the 6th Annual Neuroscience Forum and the Biotech Showcase™. Both events will be held live and are scheduled to coincide with the 41st Annual J.P. Morgan Health Care Conference in San Francisco

Yahoo | December 21, 2022

Enveric Biosciences Announces Confidential Submission of Registration Statement for the Spin-off of its Cannabinoid Business to Shareholders

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression and addiction disorders, today announced the confidential submission of a Form S-1 draft registration statement with the U.S. Securities and Exchange Commission (‘SEC’) for the spin-off its

Wallstreet:Online | November 28, 2022

Enveric Biosciences to Participate in A.G.P.’s Virtual Biotech Conference

CAMBRIDGE, Mass. — Enveric Biosciences (NASDAQ: ENVB) (”Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression and addiction disorders, today announced that Avani Kanubaddi, President & COO of Enveric Biosciences, will participate in A.G.P.’s Virtual Biotech Conference to be held from November 30, […]

Financial Post | November 16, 2022

Enveric Biosciences to Participate in Wonderland: Miami on November 3-5, 2022

CAMBRIDGE, Mass., November 01, 2022--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression and addiction disorders, today announced that Dr. Joseph Tucker, Chief Executive Officer of Enveric Biosciences, will participate in Wonderland: Miami hosted by Microdose to be held at the Mana Wynwood Convention Center in Miami, FL on November 3-5, 2022.

Yahoo | November 1, 2022

Enveric abandons EVM101 psilocybin drug program in favor of EB-373 for anxiety disorders

Cannabis drugmaker Enveric Biosciences (ENVB) on Monday said it discontinued the development of its first generation EVM101 program of psilocybin targeting cancer…

Seeking Alpha | October 24, 2022

Read More 'ENVB' Stories Here

ENVB Price Returns

1-mo 10.77%
3-mo -6.19%
6-mo -58.68%
1-year -90.71%
3-year -98.91%
5-year N/A
YTD 38.46%
2022 -95.53%
2021 -78.17%
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6546 seconds.